AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28599608 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain Function Index (BFI)
Number of subjects: 720
Study 28599647 — intervention group
Group type: EXPERIMENTAL
Intervention: Side-lying thrust spinal manipulation (SM) for 12 sessions over 6 weeks.
Number of subjects: 82
Study 28599647 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand-held global stiffness (GS) at L3 and automated GS measurements.
Number of subjects: 82
Study 28599647 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexion and extension flexion-relaxation ratio (FRR) measurements.
Number of subjects: 82
Study 28599667 — intervention group
Group type: EXPERIMENTAL
Intervention: Multipolar CRT-d
Number of subjects: 195
Study 28599667 — intervention group
Group type: COMPARATOR
Intervention: Bipolar CRT-d
Number of subjects: 195
Study 28600132 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin 1·8 mg/kg once every 3 weeks for up to 16 cycles
Number of subjects: 131
Study 28600132 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice (oral methotrexate 5-50 mg once per week or oral bexarotene 300 mg/m2)
Number of subjects: 131
Study 28600132 — intervention group
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Number of subjects: 131
Study 28600132 — intervention group
Group type: COMPARATOR
Intervention: Physician's choice
Number of subjects: 131
Study 28600387 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic testing
Number of subjects: 375
Study 28600387 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad multiphenotype genetic testing
Number of subjects: 375
Study 28600603 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol dependence (n = 446)
Number of subjects: 700
Study 28600603 — intervention group
Group type: COMPARATOR
Intervention: No alcohol dependence (n = 254)
Number of subjects: 700
Study 28600603 — intervention group
Group type: EXPERIMENTAL
Intervention: Recent risky alcohol use
Number of subjects: 700
Study 28600694 — intervention group
Group type: EXPERIMENTAL
Intervention: STARR with Contour Transtar
Number of subjects: 113
Study 28601192 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance-Guided Focused Ultrasound Surgery
Number of subjects: 0
Study 28601434 — intervention group
Group type: EXPERIMENTAL
Intervention: Moroctocog alfa (AF-CC) 50 IU/kg IV
Number of subjects: 13
Study 28601641 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant (0.4 mg/kg; maximum 30 mg)
Number of subjects: 32
Study 28601826 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin and chloroquine
Number of subjects: 0
Study 28601828 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronous resection of the primary and liver metastases
Number of subjects: 0
Study 28601828 — intervention group
Group type: EXPERIMENTAL
Intervention: Resection of the metastatic disease as the first step (liver-first approach)
Number of subjects: 0
Study 28601828 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 28602520 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Luminance Questionnaire (LLQ)
Number of subjects: 113
Study 28602587 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabrasion with thin split thickness grafting
Number of subjects: 0
Study 28602587 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidermal cell suspension spray
Number of subjects: 0
Study 28602587 — intervention group
Group type: EXPERIMENTAL
Intervention: Suction blister epidermal minigrafting
Number of subjects: 0
Study 28602587 — intervention group
Group type: EXPERIMENTAL
Intervention: Minigrafting
Number of subjects: 0
Study 28602587 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultured epithelium
Number of subjects: 0
Study 28602587 — intervention group
Group type: EXPERIMENTAL
Intervention: Noncultured keratinocyte suspension
Number of subjects: 0
Study 28602587 — intervention group
Group type: EXPERIMENTAL
Intervention: Chip skin grafting
Number of subjects: 0
Study 28602585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib 400 mg once per day for six consecutive 28-day cycles
Number of subjects: 97
Study 28602585 — intervention group
Group type: EXPERIMENTAL
Intervention: Fedratinib
Number of subjects: 97
Study 28603514 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of phenylephrine on the dorsal forearm
Number of subjects: 52
Study 28603514 — intervention group
Group type: EXPERIMENTAL
Intervention: Iontophoresis of acetylcholine
Number of subjects: 52
Study 28603514 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathetic skin responses, autonomic and motor symptoms evaluation
Number of subjects: 52
Study 28603514 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin biopsies
Number of subjects: 52
Study 28605423 — intervention group
Group type: EXPERIMENTAL
Intervention: SAPIEN 3 balloon-expandable transcatheter heart valve
Number of subjects: 1946
Study 28605428 — intervention group
Group type: EXPERIMENTAL
Intervention: Carpentier-Edwards PERIMOUNT™ Magna Ease™ aortic valve with RESILIA™ tissue (Model 11000A)
Number of subjects: 689
Study 28606146 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIMMER diabetes prevention intervention (combined lifestyle intervention with dietary and physical activity components)
Number of subjects: 240
Study 28606488 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Illness Perception Questionnaire (B-IPQ)
Number of subjects: 585
Study 28606488 — intervention group
Group type: EXPERIMENTAL
Intervention: B-IPQ 'Consequences' subscale
Number of subjects: 585
Study 28606598 — intervention group
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Number of subjects: 150
Study 28606966 — intervention group
Group type: EXPERIMENTAL
Intervention: Obesity
Number of subjects: 470
Study 28606999 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 9953
Study 28606999 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiography
Number of subjects: 9953
Study 28606999 — intervention group
Group type: EXPERIMENTAL
Intervention: Early dual antiplatelet treatment
Number of subjects: 9953
Study 28606999 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI timing
Number of subjects: 9953
Study 28606999 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality in high-risk and very-high-risk patients who received PCI
Number of subjects: 9953
Study 28606999 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-high-risk patients
Number of subjects: 9953
Study 28606999 — intervention group
Group type: COMPARATOR
Intervention: Early risk assessment
Number of subjects: 9953
Study 28607547 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg + Domperidone 30 mg (group 1)
Number of subjects: 60
Study 28607547 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg (group 2)
Number of subjects: 60
Study 28607686 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD toolkit intervention including practice audit and feedback, printed educational materials, electronic decision support, reminders, and implementation support.
Number of subjects: 0
Study 28607686 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD toolkit intervention
Number of subjects: 0
Study 28607686 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 0
Study 28607691 — intervention group
Group type: EXPERIMENTAL
Intervention: MIS416 administered once weekly for four weeks, then once weekly for up to 12 weeks at a dose of 500 µg/week.
Number of subjects: 0
Study 28607708 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriflunomide added to stable-dose GA
Number of subjects: 0
Study 28607708 — intervention group
Group type: COMPARATOR
Intervention: Glatiramer acetate (GA) alone
Number of subjects: 0
Study 28607743 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous peginterferon beta-1a every 2 weeks
Number of subjects: 100
Study 28607743 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 28608617 — intervention group
Group type: EXPERIMENTAL
Intervention: Canagliflozin 100 mg added to teneligliptin 20 mg orally once daily for 52 weeks
Number of subjects: 153
Study 28609404 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serology positive infants aged 0-3 months
Number of subjects: 203
Study 28609404 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serology positive infants aged 4-8 months
Number of subjects: 203
Study 28609404 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serology positive infants/children aged 9-18 months
Number of subjects: 203
Study 28609404 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of maternal serology to define HIV exposure
Number of subjects: 203
Study 28610605 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 weeks of directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin
Number of subjects: 93
Study 28610605 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 weeks of directly observed peg-interferon alfa-2b (PEG-IFN) and self-administered ribavirin
Number of subjects: 93
Study 28610605 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 93
Study 28610605 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment completion
Number of subjects: 93
Study 28610605 — intervention group
Group type: COMPARATOR
Intervention: 12 weeks of therapy vs 24 weeks
Number of subjects: 93
Study 28611030 — intervention group
Group type: EXPERIMENTAL
Intervention: CTG expansion size
Number of subjects: 855
Study 28611037 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg/day) for 2 weeks
Number of subjects: 16
Study 28611125 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafamidis
Number of subjects: 0
Study 28611125 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28611126 — intervention group
Group type: EXPERIMENTAL
Intervention: Left Ventricular Assist Device (LVAD) therapy
Number of subjects: 0
Study 28611126 — intervention group
Group type: COMPARATOR
Intervention: Optimal medical management
Number of subjects: 0
Study 28611687 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Number of subjects: 0
Study 28611687 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28611778 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg-Interferon Lambda Treatment
Number of subjects: 0
Study 28612225 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol (EP)
Number of subjects: 67
Study 28612225 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice (TPC)
Number of subjects: 67
Study 28612237 — intervention group
Group type: EXPERIMENTAL
Intervention: L-thyroxine
Number of subjects: 1454
Study 28612237 — intervention group
Group type: COMPARATOR
Intervention: No L-thyroxine
Number of subjects: 1454
Study 28612680 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile stroke unit
Number of subjects: 693
Study 28612680 — intervention group
Group type: COMPARATOR
Intervention: Standard management
Number of subjects: 693
Study 28613220 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injections of Lucentis
Number of subjects: 67
Study 28614132 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic opioid users
Number of subjects: 37
Study 28614132 — intervention group
Group type: COMPARATOR
Intervention: Opioid-naïve patients
Number of subjects: 37
Study 28614154 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intralesional ziv-aflibercept (0.1 mL to 0.3 mL, 2.5 mg to 7.5 mg)
Number of subjects: 4
Study 28614154 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intralesional ziv-aflibercept
Number of subjects: 4
Study 28614791 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAd63-MVA heterologous prime-boost regimen, delivered intramuscularly with an 8-week interval.
Number of subjects: 24
Study 28614995 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin inhalation powder (TIP) via T-326 inhaler
Number of subjects: 60
Study 28614995 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS) via nebulizer
Number of subjects: 60
Study 28614995 — intervention group
Group type: COMPARATOR
Intervention: Colistimethate sodium (COLI) via nebulizer
Number of subjects: 60
Study 28614995 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin inhalation solution (TIS) and Colistimethate sodium (COLI) via nebulizers
Number of subjects: 60
Study 28615158 — intervention group
Group type: EXPERIMENTAL
Intervention: PULSED orocutaneous intervention
Number of subjects: 180
Study 28615158 — intervention group
Group type: COMPARATOR
Intervention: SHAM (non-pulsing) orocutaneous intervention
Number of subjects: 180
Study 28615265 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intake from food and supplements; specific details on dosage and duration not available.
Number of subjects: 0
Study 28615277 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI session combined with electroencephalography (EEG)
Number of subjects: 30
Study 28615277 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography session
Number of subjects: 30
Study 28615277 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial magnetic stimulation (TMS) combined with EEG (TMS/EEG) session
Number of subjects: 30
Study 28615277 — intervention group
Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 30
Study 28615279 — intervention group
Group type: EXPERIMENTAL
Intervention: MOAT (Medicines Optimisation Assessment Tool)
Number of subjects: 1500
Study 28615279 — intervention group
Group type: EXPERIMENTAL
Intervention: Data collection by pharmacists
Number of subjects: 1500
Study 28615279 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariable logistic regression models
Number of subjects: 1500
Study 28615279 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootstrapping
Number of subjects: 1500
Study 28615279 — intervention group
Group type: EXPERIMENTAL
Intervention: Simplified scoring system
Number of subjects: 1500
Study 28615304 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen exposure
Number of subjects: 0
Study 28615304 — intervention group
Group type: COMPARATOR
Intervention: Control (no ibuprofen exposure)
Number of subjects: 0
Study 28615374 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional status, diet, and stimulation
Number of subjects: 0
Study 28616291 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control (<120 mmHg)
Number of subjects: 360
Study 28616291 — intervention group
Group type: COMPARATOR
Intervention: Conventional blood pressure control (<140 mmHg)
Number of subjects: 360
Study 28616804 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 158
Study 28616804 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 158
Study 28616853 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceramide dominant therapeutic moisturizer applied twice daily for 12 weeks
Number of subjects: 58
Study 28617144 — intervention group
Group type: EXPERIMENTAL
Intervention: Betrixaban
Number of subjects: 0
Study 28617144 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 28618192 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Buddy App
Number of subjects: 40
Study 28618293 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous EEG data collection
Number of subjects: 12
Study 28618864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteroidetes/Firmicutes-ratio in men
Number of subjects: 29
Study 28618864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteroidetes/Firmicutes-ratio and peripheral insulin sensitivity in men
Number of subjects: 29
Study 28618864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteroidetes/Firmicutes-ratio and peripheral insulin sensitivity after adjustment
Number of subjects: 29
Study 28618864 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacteroidetes/Firmicutes-ratio and hepatic insulin sensitivity
Number of subjects: 29
Study 28619014 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum VEGF levels
Number of subjects: 269
Study 28619014 — intervention group
Group type: EXPERIMENTAL
Intervention: High serum bFGF levels
Number of subjects: 269
Study 28619014 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum VEGF levels
Number of subjects: 269
Study 28619014 — intervention group
Group type: EXPERIMENTAL
Intervention: Histological response, progression-free survival, overall survival
Number of subjects: 269
Study 28619014 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood or urinary bFGF levels
Number of subjects: 269
Study 28619091 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy
Number of subjects: 97
Study 28619091 — intervention group
Group type: COMPARATOR
Intervention: Postoperative KUB
Number of subjects: 97
Study 28619116 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual low-threshold physical activity intervention with counseling from a personal coach during and 3 months after chemotherapy
Number of subjects: 18
Study 28619117 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolemia (HoFH)
Number of subjects: 241
Study 28619117 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial hypercholesterolemia (HeFH)
Number of subjects: 241
Study 28619117 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 241
Study 28619117 — intervention group
Group type: EXPERIMENTAL
Intervention: FH status
Number of subjects: 241
Study 28619556 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Janus kinase inhibitors
Number of subjects: 0
Study 28619704 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 STOPP rules implemented as EMR alerts during a 16-week intervention period.
Number of subjects: 28
Study 28619704 — intervention group
Group type: COMPARATOR
Intervention: Control group did not receive the 40 STOPP rules but received other alerts.
Number of subjects: 28
Study 28619764 — intervention group
Group type: EXPERIMENTAL
Intervention: VATS lobectomy
Number of subjects: 600
Study 28619764 — intervention group
Group type: COMPARATOR
Intervention: Lobectomy using thoracotomy
Number of subjects: 600
Study 28619986 — intervention group
Group type: EXPERIMENTAL
Intervention: Low physical activity
Number of subjects: 2125
Study 28619986 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension
Number of subjects: 2125
Study 28619986 — intervention group
Group type: EXPERIMENTAL
Intervention: All 8 risk factors combined
Number of subjects: 2125
Study 28619986 — intervention group
Group type: EXPERIMENTAL
Intervention: All risk factors
Number of subjects: 2125
Study 28619986 — intervention group
Group type: EXPERIMENTAL
Intervention: Most risk factors
Number of subjects: 2125
Study 28619986 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 risk factors
Number of subjects: 2125
Study 28620012 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with NAFL
Number of subjects: 0
Study 28620012 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with T2DM
Number of subjects: 0
Study 28620012 — intervention group
Group type: COMPARATOR
Intervention: Control (CON) subjects
Number of subjects: 0
Study 28620382 — intervention group
Group type: EXPERIMENTAL
Intervention: CSF-470 vaccine plus Bacillus Calmette-Guerin (BCG) and recombinant human granulocyte macrophage-colony stimulating factor (rhGM-CSF)
Number of subjects: 31
Study 28620382 — intervention group
Group type: COMPARATOR
Intervention: Medium-dose Interferon Alpha 2B
Number of subjects: 31
Study 28620471 — intervention group
Group type: EXPERIMENTAL
Intervention: Plant sterol-enriched spread (3 g/d)
Number of subjects: 240
Study 28620471 — intervention group
Group type: COMPARATOR
Intervention: Placebo spread
Number of subjects: 240
Study 28620528 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal/mild stimulation IVF (mIVF)
Number of subjects: 1173
Study 28620528 — intervention group
Group type: EXPERIMENTAL
Intervention: Low oocyte yield group
Number of subjects: 1173
Study 28620528 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermediate oocyte yield group
Number of subjects: 1173
Study 28620528 — intervention group
Group type: EXPERIMENTAL
Intervention: High oocyte yield group
Number of subjects: 1173
Study 28622052 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab
Number of subjects: 670
Study 28622052 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab
Number of subjects: 670
Study 28622052 — intervention group
Group type: EXPERIMENTAL
Intervention: reslizumab
Number of subjects: 670
Study 28622052 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab (in patients not receiving omalizumab)
Number of subjects: 670
Study 28622052 — intervention group
Group type: EXPERIMENTAL
Intervention: reslizumab (in patients not receiving omalizumab)
Number of subjects: 670
Study 28622052 — intervention group
Group type: EXPERIMENTAL
Intervention: omalizumab (in patients not receiving omalizumab)
Number of subjects: 670
Study 28622052 — intervention group
Group type: EXPERIMENTAL
Intervention: mepolizumab (in mepolizumab-eligible patients not receiving omalizumab)
Number of subjects: 670
Study 28622052 — intervention group
Group type: EXPERIMENTAL
Intervention: reslizumab (in mepolizumab-eligible patients not receiving omalizumab)
Number of subjects: 670
Study 28622099 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent use of energy drinks with alcohol
Number of subjects: 481
Study 28622099 — intervention group
Group type: COMPARATOR
Intervention: No use of energy drinks
Number of subjects: 481
Study 28622099 — intervention group
Group type: COMPARATOR
Intervention: Energy drinks without concurrent alcohol use
Number of subjects: 481
Study 28622450 — intervention group
Group type: EXPERIMENTAL
Intervention: Cirrhosis-segmented CirrhoMeter
Number of subjects: 287
Study 28622450 — intervention group
Group type: EXPERIMENTAL
Intervention: LEV-segmented CirrhoMeter
Number of subjects: 287
Study 28622450 — intervention group
Group type: EXPERIMENTAL
Intervention: Oesophageal Capsule Endoscopy (ECE)
Number of subjects: 287
Study 28622450 — intervention group
Group type: EXPERIMENTAL
Intervention: VariScreen
Number of subjects: 287
Study 28622454 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab (intravenous)
Number of subjects: 1216
Study 28622454 — intervention group
Group type: COMPARATOR
Intervention: TNFi
Number of subjects: 1216
Study 28622959 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide 25 mg on days 1 to 21 and panobinostat 15 mg TIW for phase II
Number of subjects: 24
Study 28622959 — intervention group
Group type: COMPARATOR
Intervention: Lenalidomide 25 mg and panobinostat 20 mg
Number of subjects: 24